Prothrombin induced by vitamin K absence or antagonist‐II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C‐related cirrhosis treated with direct‐acting antiviral agents

Prothrombin induced by vitamin K absence or antagonist‐II (PIVKA‐II) and alpha fetoprotein (AFP) are biomarkers for hepatocellular carcinoma (HCC). However, their performance in patients with cirrhosis related to hepatitis C virus (HCV) treated with direct‐acting antiviral agents (DAA) is unknown.

[1]  J. Tojo,et al.  Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis , 2020, PloS one.

[2]  C. Galli,et al.  The combination of PIVKA‐II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long‐term oral therapy , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[3]  P. Lampertico,et al.  Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. , 2020, Journal of hepatology.

[4]  V. Paradis,et al.  Biological response under treatment and prognostic value of protein induced by vitamin K absence or antagonist-II in a French cohort of patients with hepatocellular carcinoma , 2019, European journal of gastroenterology & hepatology.

[5]  F. Ciardiello,et al.  Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study , 2019, Journal of Translational Medicine.

[6]  P. Lampertico,et al.  Minimal increases of serum alpha‐foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long‐term oral therapy , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[7]  Woochang Lee,et al.  Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early‐Stage Hepatocellular Carcinoma , 2019, Hepatology.

[8]  P. Lampertico,et al.  Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct‐Acting Antivirals for HCV Infection , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  L. Bolondi,et al.  Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[10]  M. Colombo,et al.  Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[11]  W. Lau,et al.  Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis. , 2018, Hepatobiliary & pancreatic diseases international : HBPD INT.

[12]  Albert Tran,et al.  Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. , 2018, Gastroenterology.

[13]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2018, Hepatology.

[14]  Giovanni Raimondo,et al.  Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. , 2018, Gastroenterology.

[15]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[16]  S. Asch,et al.  Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. , 2017, Gastroenterology.

[17]  Guohong Deng,et al.  Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data , 2017, BMC Cancer.

[18]  F. Izzo,et al.  Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection. , 2017, In vivo.

[19]  M. Kudo,et al.  Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update , 2017, Hepatology International.

[20]  Guohong Deng,et al.  Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients , 2016, Scientific Reports.

[21]  L. Bolondi,et al.  Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. , 2016, Journal of hepatology.

[22]  Peter J. Richardson,et al.  Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection , 2016, Hepatology.

[23]  V. Paradis,et al.  Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. , 2015, Journal of hepatology.

[24]  J. Lee,et al.  Protein Induced by Vitamin K Antagonist-II (PIVKA-II) Is a Reliable Prognostic Factor in Small Hepatocellular Carcinoma , 2013, World Journal of Surgery.

[25]  Dominik Heider,et al.  A Combination of α-Fetoprotein and Des-γ-Carboxy Prothrombin Is Superior in Detection of Hepatocellular Carcinoma , 2013, Digestion.

[26]  Yonggoo Kim,et al.  Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. , 2013, World journal of gastroenterology.

[27]  M. Makuuchi,et al.  Clinical and molecular insights into the hepatocellular carcinoma tumour marker des‐γ‐carboxyprothrombin , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[28]  H. Imamura,et al.  AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC , 2010, Journal of Gastroenterology.

[29]  William M. Lee,et al.  Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. , 2010, Gastroenterology.

[30]  J. Marrero,et al.  Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. , 2009, Gastroenterology.

[31]  Dario Conte,et al.  Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease , 2007, Gut.

[32]  Riccardo Lencioni,et al.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.

[33]  M. Sherman,et al.  Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.